Published in J Med Chem on July 25, 2012
Target deconvolution techniques in modern phenotypic profiling. Curr Opin Chem Biol (2013) 1.08
Big data: the next frontier for innovation in therapeutics and healthcare. Expert Rev Clin Pharmacol (2014) 0.97
PubChem applications in drug discovery: a bibliometric analysis. Drug Discov Today (2014) 0.95
SemFunSim: a new method for measuring disease similarity by integrating semantic and gene functional association. PLoS One (2014) 0.94
Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity. AMIA Annu Symp Proc (2014) 0.89
Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders. Annu Rev Pharmacol Toxicol (2015) 0.89
Efficacy and safety of tribendimidine against Clonorchis sinensis. Clin Infect Dis (2012) 0.87
Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. Clin Cancer Res (2015) 0.87
Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent. Ecancermedicalscience (2014) 0.86
Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro Oncol (2014) 0.86
The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Oncotarget (2017) 0.85
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. Oncotarget (2014) 0.85
Construction of drug network based on side effects and its application for drug repositioning. PLoS One (2014) 0.84
Proteochemometric modeling in a Bayesian framework. J Cheminform (2014) 0.83
Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen. Sci Rep (2015) 0.82
Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation. Oncotarget (2015) 0.77
Drug repurposing a reality: from computers to the clinic. Expert Rev Clin Pharmacol (2013) 0.76
Improving chemical similarity ensemble approach in target prediction. J Cheminform (2016) 0.76
Naturally occurring polyphenol, morin hydrate, inhibits enzymatic activity of N-methylpurine DNA glycosylase, a DNA repair enzyme with various roles in human disease. Bioorg Med Chem (2015) 0.76
DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing. BMC Bioinformatics (2016) 0.75
Cadherin-11 expression is upregulated in invasive human breast cancer. Oncol Lett (2016) 0.75
ChemDes: an integrated web-based platform for molecular descriptor and fingerprint computation. J Cheminform (2015) 0.75
The purpose of repurposing. Oncotarget (2017) 0.75
On the Integration of In Silico Drug Design Methods for Drug Repurposing. Front Pharmacol (2017) 0.75
SCOP: a structural classification of proteins database for the investigation of sequences and structures. J Mol Biol (1995) 74.88
The price of innovation: new estimates of drug development costs. J Health Econ (2003) 23.43
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov (2010) 14.09
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Drug target identification using side-effect similarity. Science (2008) 9.24
Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov (2004) 7.57
A critical assessment of docking programs and scoring functions. J Med Chem (2006) 5.78
Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med (2011) 5.77
Benchmarking sets for molecular docking. J Med Chem (2006) 5.57
Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med (2011) 5.30
Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem (2006) 3.85
The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med (2011) 3.80
A review of protein-small molecule docking methods. J Comput Aided Mol Des (2002) 3.25
PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol (2011) 3.22
Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol (2007) 3.17
In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol (1983) 2.91
Large-scale chemical dissection of mitochondrial function. Nat Biotechnol (2008) 2.91
Type II cadherin ectodomain structures: implications for classical cadherin specificity. Cell (2006) 2.85
Systems chemical biology. Nat Chem Biol (2007) 2.35
Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol (2009) 2.35
Docking and scoring--theoretically easy, practically impossible? Curr Med Chem (2006) 2.18
Imatinib as a paradigm of targeted therapies. Adv Cancer Res (2004) 2.11
2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov (2008) 2.00
Mining for therapeutic gold. Nat Rev Drug Discov (2011) 1.88
Shape variation in protein binding pockets and their ligands. J Mol Biol (2007) 1.83
A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc Natl Acad Sci U S A (2009) 1.82
High-throughput docking for lead generation. Curr Opin Chem Biol (2001) 1.74
In vitro models of vasculogenesis and angiogenesis. Lab Invest (2001) 1.64
Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput Biol (2011) 1.51
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol (2011) 1.26
Structure-based drug design: docking and scoring. Curr Protein Pept Sci (2007) 1.25
Drugs in other drugs: a new look at drugs as fragments. Drug Discov Today (2006) 1.19
A computational approach to finding novel targets for existing drugs. PLoS Comput Biol (2011) 1.17
Computational analysis of ligand relationships within target families. Curr Opin Chem Biol (2008) 1.14
Repurposing libraries of eukaryotic protein kinase inhibitors for antibiotic discovery. Proc Natl Acad Sci U S A (2009) 1.10
Docking screens: right for the right reasons? Curr Top Med Chem (2009) 1.05
Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum (2002) 1.02
Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain (2006) 1.00
Celecoxib inhibits production of MMP and NO via down-regulation of NF-kappaB and JNK in a PGE2 independent manner in human articular chondrocytes. Rheumatol Int (2007) 1.00
Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther (2011) 0.96
Drug repositioning and pharmacophore identification in the discovery of hookworm MIF inhibitors. Chem Biol (2011) 0.96
Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol (2007) 0.96
The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway. J Neurooncol (2011) 0.95
Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. Biochem Biophys Res Commun (2010) 0.94
Identify drug repurposing candidates by mining the protein data bank. Brief Bioinform (2011) 0.93
Staurosporine induces rapid homotypic intercellular adhesion of U937 cells via multiple kinase activation. Br J Pharmacol (2003) 0.89
Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism. Cancer Chemother Pharmacol (2010) 0.86
COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. OMICS (2011) 0.82
Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy. Anticancer Agents Med Chem (2010) 0.81
Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression. Biosci Rep (2012) 0.80
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med (2009) 2.17
The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell (2006) 1.91
IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol Biol Cell (2003) 1.86
Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol (2004) 1.80
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med (2011) 1.79
Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest (2010) 1.73
GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem (2009) 1.56
High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One (2010) 1.54
Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol Cancer (2006) 1.51
VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biol Ther (2010) 1.49
AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther (2009) 1.48
Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers. Clin Prostate Cancer (2003) 1.44
Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta. Chem Biol (2007) 1.44
Wnt-3a-dependent cell motility involves RhoA activation and is specifically regulated by dishevelled-2. J Biol Chem (2004) 1.43
Trans-repression of beta-catenin activity by nuclear receptors. J Biol Chem (2003) 1.37
The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene (2005) 1.35
Voltage-sensitive ion channels and cancer. Cancer Metastasis Rev (2006) 1.34
Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res (2006) 1.32
Tumor suppressor RARRES1 interacts with cytoplasmic carboxypeptidase AGBL2 to regulate the α-tubulin tyrosination cycle. Cancer Res (2011) 1.28
Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Mol Cell Biol (2008) 1.27
An alternatively spliced cadherin-11 enhances human breast cancer cell invasion. Cancer Res (2002) 1.26
Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. J Biol Chem (2012) 1.25
Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. J Pharmacol Exp Ther (2009) 1.24
Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. Psychopharmacology (Berl) (2010) 1.20
STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci U S A (2013) 1.20
G-DOC: a systems medicine platform for personalized oncology. Neoplasia (2011) 1.18
Wnt/beta-catenin and retinoic acid receptor signaling pathways interact to regulate chondrocyte function and matrix turnover. J Biol Chem (2009) 1.16
Design, synthesis and evaluation of novel hydroxyamides as orally available anticonvulsants. Bioorg Med Chem (2004) 1.13
Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men. Int J Oncol (2009) 1.13
Mechanical force modulates global gene expression and beta-catenin signaling in colon cancer cells. J Cell Sci (2007) 1.11
Disulfide bond assignments of secreted Frizzled-related protein-1 provide insights about Frizzled homology and netrin modules. J Biol Chem (2001) 1.10
Wnt signaling promotes proliferation and stemness regulation of spermatogonial stem/progenitor cells. Reproduction (2009) 1.09
Cell-context dependent TCF/LEF expression and function: alternative tales of repression, de-repression and activation potentials. Crit Rev Eukaryot Gene Expr (2011) 1.09
Structure-based discovery of a boronic acid bioisostere of combretastatin A-4. Chem Biol (2005) 1.07
YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS One (2011) 1.07
Voltage-gated sodium channel blockers as cytostatic inhibitors of the androgen-independent prostate cancer cell line PC-3. Mol Cancer Ther (2003) 1.06
Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer (2008) 1.04
Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget (2012) 1.04
Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole. Mol Pharmacol (2007) 1.04
PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. Oncogene (2005) 1.03
Cross-regulation of signaling pathways: an example of nuclear hormone receptors and the canonical Wnt pathway. Exp Cell Res (2010) 1.02
Asymmetric synthesis of 2,3-dihydro-2-arylquinazolin-4-ones: methodology and application to a potent fluorescent tubulin inhibitor with anticancer activity. J Med Chem (2008) 1.02
Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats. Psychopharmacology (Berl) (2011) 1.02
Assessing the effects of chronic sazetidine-A delivery on nicotine self-administration in both male and female rats. Psychopharmacology (Berl) (2012) 1.00
Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse. Front Genet (2013) 0.99
The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J Biol Chem (2002) 0.99
N-terminal extension of N-methylpurine DNA glycosylase is required for turnover in hypoxanthine excision reaction. J Biol Chem (2007) 0.97
Synthesis and evaluation of hermitamides A and B as human voltage-gated sodium channel blockers. Bioorg Med Chem (2011) 0.97
Big data: the next frontier for innovation in therapeutics and healthcare. Expert Rev Clin Pharmacol (2014) 0.97
Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. PLoS One (2009) 0.96
Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Mol Cancer Ther (2008) 0.96
DIM (3,3'-diindolylmethane) confers protection against ionizing radiation by a unique mechanism. Proc Natl Acad Sci U S A (2013) 0.96
DDN: a caBIG® analytical tool for differential network analysis. Bioinformatics (2011) 0.96
Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer. Am J Transl Res (2013) 0.96
Post-transcriptional regulation of cadherin-11 expression by GSK-3 and beta-catenin in prostate and breast cancer cells. PLoS One (2009) 0.95
βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology (2015) 0.95
Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg Med Chem (2007) 0.95
Small molecule metabolite extraction strategy for improving LC/MS detection of cancer cell metabolome. J Biomol Tech (2011) 0.95
Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. Cancer Cell (2012) 0.95
Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget (2013) 0.94
Development of a novel assay for human tyrosyl DNA phosphodiesterase 2. Anal Biochem (2011) 0.93
Small molecule inducers of angiogenesis for tissue engineering. Tissue Eng (2006) 0.92
Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases. Inflamm Bowel Dis (2012) 0.92
A pharmacophore derived phenytoin analogue with increased affinity for slow inactivated sodium channels exhibits a desired anticonvulsant profile. Neuropharmacology (2006) 0.92
Role of Sox-9, ER81 and VE-cadherin in retinoic acid-mediated trans-differentiation of breast cancer cells. PLoS One (2008) 0.91
A global benchmark study using affinity-based biosensors. Anal Biochem (2008) 0.91
Biomarkers of WNT signaling. Cancer Biomark (2007) 0.91
Tumor Suppressor RARRES1 Regulates DLG2, PP2A, VCP, EB1, and Ankrd26. J Cancer (2010) 0.90
Odors Pulsed at Wing Beat Frequencies are Tracked by Primary Olfactory Networks and Enhance Odor Detection. Front Cell Neurosci (2010) 0.90
Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells. Bioorg Med Chem (2011) 0.90
RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target Signature Predictions. Comb Chem High Throughput Screen (2015) 0.90
Excised damaged base determines the turnover of human N-methylpurine-DNA glycosylase. DNA Repair (Amst) (2009) 0.90
Ligand-based design and synthesis of novel sodium channel blockers from a combined phenytoin-lidocaine pharmacophore. Bioorg Med Chem (2008) 0.89
The ezrin metastatic phenotype is associated with the initiation of protein translation. Neoplasia (2012) 0.89
Chemistry and pharmacological studies of 3-alkoxy-2,5-disubstituted-pyridinyl compounds as novel selective α4β2 nicotinic acetylcholine receptor ligands that reduce alcohol intake in rats. J Med Chem (2013) 0.88
Preclinical magnetic resonance imaging and systems biology in cancer research: current applications and challenges. Am J Pathol (2012) 0.88
Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis. Cancer Res (2003) 0.88
The CPTAC Data Portal: A Resource for Cancer Proteomics Research. J Proteome Res (2015) 0.88
Informatics and data quality at collaborative multicenter Breast and Colon Cancer Family Registries. J Am Med Inform Assoc (2012) 0.88
Fluorescent epigenetic small molecule induces expression of the tumor suppressor ras-association domain family 1A and inhibits human prostate xenograft. J Med Chem (2010) 0.87
The E6 oncoprotein from HPV16 enhances the canonical Wnt/β-catenin pathway in skin epidermis in vivo. Mol Cancer Res (2011) 0.87
Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genet Med (2012) 0.87
VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biol Ther (2011) 0.86
Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6. Bioorg Med Chem (2003) 0.86
1E7-03, a low MW compound targeting host protein phosphatase-1, inhibits HIV-1 transcription. Br J Pharmacol (2014) 0.86
Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS One (2012) 0.86
Detailed Characterization of Local Field Potential Oscillations and Their Relationship to Spike Timing in the Antennal Lobe of the Moth Manduca sexta. Front Neuroeng (2011) 0.85
Putative biomarkers and targets of estrogen receptor negative human breast cancer. Int J Mol Sci (2011) 0.85
Expression, purification and characterization of codon-optimized human N-methylpurine-DNA glycosylase from Escherichia coli. Protein Expr Purif (2007) 0.85
Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor. Mol Cancer Ther (2011) 0.85
Retinoic acid mediates regulation of network formation by COUP-TFII and VE-cadherin expression by TGFbeta receptor kinase in breast cancer cells. PLoS One (2010) 0.85
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. Oncotarget (2014) 0.85
Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology. Curr Pharm Des (2016) 0.85